购物车
全部删除
您的购物车当前为空
SJ11646 是一种Dasatinib基础上的LCKPROTAC降解剂,DC50为 0.00838 pM。它在LCK激活的T细胞急性淋巴细胞白血病 (T-ALL) 细胞及原发性白血病样本中展现出强大细胞毒性,能够显著延长LCK信号的抑制时间,诱导T-ALL细胞凋亡 (apoptosis)。此外,SJ11646 还能以高亲和力结合51种人类激酶,尤其是ABL1、KIT和DDR1。在T-ALL小鼠模型中,SJ11646显示出卓越的抗白血病效果。

SJ11646 是一种Dasatinib基础上的LCKPROTAC降解剂,DC50为 0.00838 pM。它在LCK激活的T细胞急性淋巴细胞白血病 (T-ALL) 细胞及原发性白血病样本中展现出强大细胞毒性,能够显著延长LCK信号的抑制时间,诱导T-ALL细胞凋亡 (apoptosis)。此外,SJ11646 还能以高亲和力结合51种人类激酶,尤其是ABL1、KIT和DDR1。在T-ALL小鼠模型中,SJ11646显示出卓越的抗白血病效果。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 10-14周 | |
| 50 mg | 待询 | 10-14周 |
SJ11646 相关产品
| 产品描述 | SJ11646 is a Dasatinib-based LCK PROTAC degrader with a DC50 of 0.00838 pM. It exhibits potent cytotoxicity against LCK-activated T-cell acute lymphoblastic leukemia (T-ALL) cells and primary leukemia samples, significantly prolongs LCK signal inhibition, and induces apoptosis in T-ALL cells. SJ11646 binds with high affinity to 51 human kinases, particularly ABL1, KIT, and DDR1. In mouse models of T-ALL, SJ11646 demonstrates exceptional anti-leukemic efficacy. |
| 靶点活性 | Lck:0.00838 pM (DC50) |
| 分子量 | 746.28 |
| 分子式 | C36H40ClN9O5S |
| CAS No. | 2933135-82-9 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容